Sinovac Names Danny Chung Chief Financial Officer
BEIJING, May 14, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, has appointed Mr. Danny Chung as Chief Financial Officer, effective immediately. Ms. Nan Wang, who has served as interim Chief Financial Officer since August 2011...
Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
BEIJING, May 8, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2012 before market on Tuesday, May 15, 2012. The Company will host a confe...
Sinovac Participates in Goldman Sachs/Gao Hua Healthcare Corporate Day in Hong Kong
BEIJING, April 12, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that management will attend the April 2012 Goldman Sachs/Gao Hua Healthcare Corporate Day in Hong Kong. Ms. Nan Wang, Interim Chief Financial Of...
Sinovac Files Annual Report on Form 20-F
BEIJING, April 12, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2011 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2011 on A...
Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results
BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and preliminary full year financial results for the period ended December 31, 2011. Financial Highlights -- S...
Sinovac Announces Director Appointment
BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the appointment of Mr. Meng Mei as an independent director to fill the vacancy created by the resignation of Ms. Chup Hung Mok. Mr. Mei has also...
Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine
BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that the positive Phase I clinical data for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD...
Sinovac to Host Conference Call to Report Fourth Quarter 2011 Unaudited Financial Results
BEIJING, March 21, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the fourth quarter ended December 31, 2011 before market on Thursday, March 29, 2012. The Company will ho...
Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement
BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based on the departure of Ms. Chup Hung Mok from the Company's Board of Directors ef...
Sinovac to Present at 23rd Annual Piper Jaffray Health Care Conference and HK/China Mini Conference 2011 (Healthcare)
BEIJING, Nov. 23, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference that will be held on November 29th and 30th at The New York Palace ...
/C O R R E C T I O N -- Sinovac Biotech Ltd./
BEIJING, Nov. 16, 2011 /PRNewswire-Asia/ -- In the news release, "Sinovac Reports Unaudited Third Quarter 2011 Financial Results" with financial tables, issued on November 14, 2011 by Sinovac Biotech Ltd. over PR Newswire, we are advised by the Company that the third sentence of the fourth paragrap...
Sinovac Reports Unaudited Third Quarter 2011 Financial Results
BEIJING, Nov. 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011. *Financial Highlights* -- Sales in the third quarter...
Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the positive top-line results from its phase II clinical trial for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which ...
Sinovac Presents at Cowen and Company China Opportunity Conference
BEIJING, Nov. 8, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the Cowen and Company China Opportunity Conference that will be held on November 15 - 16 at The St. Regis Beijing. The Si...
Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
BEIJING, Nov. 7, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2011 before market open on Monday, November 14, 2011. The Company wil...
Sinovac Selected by Beijing CDC to Supply Seasonal Influenza Vaccine Anflu(R) to Beijing Citizens
BEIJING, Oct. 13, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the four manufacturers to supply seas...
Sinovac's Animal Rabies Vaccine RabEnd Receives Production License
BEIJING, Sept. 27, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that Tangshan Yian Biological Engineering Co., Ltd., its wholly owned subsidiary, received the production license for its developed inactivated ...
Sinovac to Participate in Four Investor Conferences in September 2011
BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, Ms. Nan Wang, Interim Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are sched...
Sinovac Reports Unaudited Second Quarter 2011 Financial Results
BEIJING, Aug. 12, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011. *Second Quarter 2011 Financial Highlights* -- Sales incr...
Sinovac Receives GMP Certificate in Mexico for Seasonal Flu Vaccine and Hepatitis A Vaccine
BEIJING, Aug. 11, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has obtained the GMP certificate for its seasonal flu vaccine and hepatitis A vaccine from the Mexican regulatory authority, the Federal ...
